Pseudo-differentiation syndrome

Dina Khalaf, Fathi Jehani
  • Fathi Jehani
    Affiliation not present


A patient with relapsed acute myeloid leukemia (AML) (M2) FAB classification developed a differentiating syndrome upon receiving Decitabine therapy given with palliative intent. The patient presented with high grade fever, constitutional symptoms and severe chest symptoms with no underlying lung condition. Chest x-ray (CXR) showed diffuse pulmonary infiltrates. Septic work up followed by intravenous broad spectrum antimicrobials did not improve his condition. Pan cultures’ results were repeatedly negative. Treatment with high dose Dexamethasone (DXM) resulted in marked clinical and radiological improvement.

Our patient initially presented with relapsed AML (M2) Fab classification with t (8; 21); negative FMS-like tyrosine kinase -internal tandem duplication (FLT3-ITD) which are all good prognostic factors, yet the patient had an atypical clinical course with early frequent relapses, differentiation syndrome associated with Decitabine therapy and late in his disease, he developed a granulocytic sarcoma.


Leukemia, Hypomethylating agents, ATRA

Full Text:

Submitted: 2014-06-12 16:05:22
Published: 2011-12-15 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185     •     Privacy